Category - Developments

Developments

Fibrocell, Intrexon to collaborate on joint diseases

Fibrocell Science (NASDAQ:FCSC) and Intrexon (NYSE:XON) agreed to an exclusive channel collaboration for the development of genetically-modified fibroblasts to treat chronic inflammatory and degenerative diseases of the...

January 4, 2016

Developments

Titan’s Probuphine implant gains media attention

The CBS affiliate in Philadelphia has produced a news segment about Titan Pharmaceutical’s (NASDAQ:TTNP) Probuphine implant for the maintenance treatment of opioid addiction. According to the CBS segment, experts say...

December 21, 2015

Developments

Canada clears BioLight’s IOPtiMate system

The Canadian Medical Devices Bureau has approved BioLight Life Sciences Investments’ (OTCQX:BLGTY; TASE:BOLT) IOPtiMate system for the treatment of glaucoma, allowing the company to commercialize the surgical system in...

December 21, 2015

Developments

Can-Fite gets patent in Japan for CF101

The Japan Patent Office has granted Can-Fite BioPharma (NYSE MKT:CANF) (TASE:CFBI) a patent for its lead drug candidate, CF101, for the reduction of intraocular pressure (IOP). CF101 is an A3 adenosine receptor (A3AR)...

December 17, 2015

Developments

Soricimed completes Phase 1 cancer trial with SOR-C13

Closely-held Soricimed Biopharma has reached its target enrollment and treatment duration in a Phase 1 trial to evaluate the safety and tolerability of SOR-C13 in patients with solid tumor cancers who have failed other...

December 15, 2015

Developments

BioSight posts positive leukemia results for Astarabine

Closely-held BioSight of Israel reported positive interim results in an abstract at the ASH meeting last week from a Phase 1/2a clinical study of Astarabine in leukemia patients. The aim of the study was to evaluate the...

December 15, 2015

Developments

FDA panel to review NDA for Probuphine

The FDA’s Psychopharmacologic Drugs Advisory Committee has scheduled a meeting on Jan. 12 to review the NDA for Titan Pharmaceuticals’ (NASDAQ: TTNP) Probuphine for the maintenance treatment of opioid addiction. The FDA...

December 9, 2015

Developments

Can-Fite unit completes enrollment in glaucoma Phase 2 trial

Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) subsidiary, OphthaliX (OTCQB:OPLI), has completed enrollment of 88 patients in its Phase 2 trial of CF101, an oral treatment for glaucoma. The trial is being conducted in...

December 7, 2015

Developments

Ciclofilin Pharma forms liver disease SAB

Closely-held Ciclofilin Pharmaceuticals has assembled a world-class team of scientists and clinicians for its scientific advisory board (SAB) to guide the company through its drug development program for its lead drug...

December 3, 2015

Developments

BioLight, Axella to advance CellDetect in bladder cancer

BioLight Life Sciences Investments’ (OTCQX:BLGTY; TASE:BOLT) cancer diagnostics subsidiary, Micromedic Technologies (TASE:MCTC), has entered into a collaboration agreement with Axella Research to advance the clinical...

November 30, 2015

Category - Developments

Fibrocell, Intrexon to collaborate on joint diseases

Titan’s Probuphine implant gains media attention

Canada clears BioLight’s IOPtiMate system

Can-Fite gets patent in Japan for CF101

Soricimed completes Phase 1 cancer trial with SOR-C13

BioSight posts positive leukemia results for Astarabine

FDA panel to review NDA for Probuphine

Can-Fite unit completes enrollment in glaucoma Phase 2 trial

Ciclofilin Pharma forms liver disease SAB

BioLight, Axella to advance CellDetect in bladder cancer

General

More